Opus Genetics Announces First Participant Dosed in Phase 1/2 Clinical Trial of OPGx-RDH12 Gene Therapy for Rare Inherited Childhood Blindness
Key Highlights
- ➤Opus Genetics (IRD) doses first participant in Phase 1/2 OPGx-RDH12 trial
- ➤FDA cleared OPGx-RDH12’s IND in October 2026
- ➤Global RDH12 Alliance committed up to $1.6 million for development
- ➤OPGx-RDH12 advances Opus Genetics’ third gene therapy program into clinical development
Expert Statements
George Magrath, Chief Executive Officer of Opus Genetics
“Dosing the first participant in our OPGx-RDH12 clinical trial represents another important milestone for Opus Genetics and, most importantly, for patients and families affected by this devastating form of childhood blindness”
George Magrath, Chief Executive Officer of Opus Genetics
“RDH12-LCA causes progressive vision loss beginning at a very young age, underscoring the urgency of developing treatments that may preserve retinal function before further deterioration occurs.”
George Magrath, Chief Executive Officer of Opus Genetics
“This milestone reflects the dedication of our partners at the Global RDH12 Alliance, whose collaboration has been instrumental in advancing this program into the clinic.”
George Magrath, Chief Executive Officer of Opus Genetics
“We look forward to evaluating OPGx-RDH12 as we continue advancing our pipeline of potential treatments for inherited retinal diseases.”
Kenneth Fan, Principal Investigator at Retina Consultants of Texas in Houston
“RDH12-associated Leber congenital amaurosis is a severe inherited retinal disease that can lead to significant vision loss beginning in early childhood, with no FDA approved treatment options available to patients”
Kenneth Fan, Principal Investigator at Retina Consultants of Texas in Houston
“We believe OPGx-RDH12 represents a promising gene therapy approach designed to address the underlying genetic cause of the disease.”
Kenneth Fan, Principal Investigator at Retina Consultants of Texas in Houston
“We are honored to have this opportunity to evaluate the safety and potential to preserve retinal function, with the ultimate goal of changing the course of this progressive condition.”
First participant dosed with OPGx-RDH12, an investigational gene therapy designed to address the underlying genetic cause of RDH12-associated Leber congenital amaurosis (RDH12-LCA)
Milestone advances Opus Genetics' third gene therapy program into clinical development, following FDA clearance of its Investigational New Drug application in October 2026
Get started
Create a free account to read the full story.
